CHEMOTHERAPEUTIC APPROACHES TO SOFT-TISSUE SARCOMAS

被引：19

作者：

EDMONSON, JH

机构：

[1] Department of Oncology, Mayo Medical School, Mayo Clinic, Rochester, Minnesota

来源：

SEMINARS IN SURGICAL ONCOLOGY | 1994年 / 10卷 / 05期

关键词：

GM-CSF; MOLGRAMOSTIM; IFOSFAMIDE; MITOMYCIN; DOXORUBICIN; CISPLATIN;

D O I：

10.1002/ssu.2980100508

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Conventional chemotherapy for adult type soft tissue sarcomas is not very effective. Rarely are patients with advanced soft tissue sarcomas curable by systemic chemotherapy. Thus, the benefits from chemotherapy have been equivocal even when treatment is given postoperatively to patients whose primary sarcomas have been excised. Current research is directed toward the achievement of a high percentage of complete tumor regressions in patients with advanced metastatic disease in hope that this can be translated into truly effective adjuvant therapy. Several recent new approaches to systemic treatment for soft tissue sarcomas are assessed including prospects for possible enhancement of chemotherapy by agents which stimulate cellular immunity. Some unexpectedly favorable responses to chemotherapy + granulocyte-macrophage colony-stimulating factor (GM-CSF) in an ongoing study are discussed. (C) 1994 Wiley-Liss, Inc.

引用

页码：357 / 363

页数：7

共 25 条

[1]

Antman KH, Crowley J, Balcerzak SP, Et al., An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas, J Clin Oncol, 11, pp. 1276-1285, (1993)

[2]

Edmonson JH, Ryan LM, Blum RH, Et al., Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas, J Clin Oncol, 11, pp. 1269-1275, (1993)

[3]

Edmonson JH, Long HJ, Kvols LK, Cytotoxic drugs plus subcutaneous granulocyte‐macrophage colony stimulating factor: Can molgramostim enhance antisarcoma therapy, J Natl Cancer Inst, 86, pp. 312-314, (1994)

[4]

Elias A, Ryan L, Sulkes A, Et al., Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy, J Clin Oncol, 7, pp. 1208-1216, (1989)

[5]

Steward WP, Verweij J, Somers R, Et al., Granulocyte‐macrophage colony stimulating factor allows safe escalation of dose intensity of chemotherapy in metastatic adult soft tissue sarcomas: A study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group, J Clin Oncol, 11, pp. 15-21, (1993)

[6]

Bodey GP, Rodriguez V, Murphy WK, Et al., Protected environment‐prophylactic antibiotic program for malignant sarcoma: Randomized trial during remission induction chemotherapy, Cancer, 47, pp. 2422-2429, (1981)

[7]

Raafat J, Esfehani FS, (1993)

[8]

Kessinger A, Petersen K, Bishop M, Schmit-Pokorny K, High dose therapy with autologous hematopoietic stem cell rescue for patients with metastatic soft tissue sarcoma, Proc ASCO, 13, (1994)

[9]

Bouhour D, Brunat-Mentigny M, Rivorie M, Et al., High dose chemotherapy and bone marrow support in advanced sarcomas, Proc ASCO, 13, (1994)

[10]

Elias AD, Chemotherapy for soft tissue sarcomas, Clin Orthop, 289, pp. 94-105, (1993)

← 1 2 3 →